Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
99.80
+1.28 (1.30%)
Jul 2 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 99.36 - 99.97
52 week 84.17 - 105.82
Open 99.83
Vol / Avg. 3.75M/1.58M
Mkt cap 264.09B
P/E 23.06
Div/yield 2.67/2.67
EPS 4.33
Shares 2.40B
Beta 0.56
Inst. own 10%
Sep 30, 2015
Novartis AG at Sanford C Bernstein European Strategic Decisions Conference Add to calendar
Sep 17, 2015
Novartis AG at Bank of America Merrill Lynch Global Healthcare Conference Add to calendar
Sep 16, 2015
Novartis AG at Morgan Stanley Healthcare Conference Add to calendar
Jul 21, 2015
Q2 2015 Novartis AG Earnings Release - 3:00AM EDT - Add to calendar
Jun 25, 2015
Novartis AG at JPMorgan European Healthcare Conference
Jun 18, 2015
Novartis AG Meet Novartis Management
Jun 9, 2015
Novartis AG at Goldman Sachs Healthcare Conference
May 20, 2015
Novartis AG at UBS Global Healthcare Conference
May 19, 2015
Novartis AG at Berenberg European Conference USA
Apr 23, 2015
Q1 2015 Novartis AG Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 18.33% 20.00%
Operating margin 17.61% 20.68%
EBITD margin - 31.46%
Return on average assets 7.83% 8.53%
Return on average equity 13.84% 14.69%
Employees 133,413 -
CDP Score - 94 B

Address

Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-6969511 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools ans over-the-counter products. It has four operating segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics; and consumer health, which include over-the-counter medicines (OTC).

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Joseph Jimenez Jr Chief Executive Officer, Member of the Executive Committee
Age: 55
Bio & Compensation  - Reuters
Ulrich Lehner Vice Chairman of the Board of Directors, Non-Executive Director
Age: 68
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 49
Bio & Compensation  - Reuters
Peter Kornicker Chief Compliance Officer
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 58
Bio & Compensation  - Reuters
Steven Baert Head Human Resources and Member of the Executive Committee
Age: 40
Bio & Compensation  - Reuters
Michele Galen Head Communications
Bio & Compensation  - Reuters
Paul van Arkel Head of Corporate Strategy and External Affairs
Bio & Compensation  - Reuters
Erwin Vanhaecke Ph.D. Head Novartis Group Quality
Bio & Compensation  - Reuters